Skip to main content
Loading...
Menu social network
LinkedIn
Facebook
X
Youtube
Menu top
Assistance
User account menu
Log in
Main navigation
Home
Programme
Download the app
App
Download the app
App
Menu
Login
Close
Main navigation mobile
Home
Programme
Menu top
Assistance
Menu social network
LinkedIn
Facebook
X
Youtube
24 results
D1.349 - Early Diagnosis of WHIM Syndrome in Infancy: A Case with a De Novo CXCR4 Mutation
D1.348 - Retrospective Evaluation of Laboratory and Clinical Characteristics of Pediatric Patients Diagnosed with IgG Subclass Deficiency and Receiving Intravenous Immunoglobulin Replacement Therapy
D1.350 - Selective IgA deficiency and its association with allergic and autoimmune diseases
D1.351 - Chronic urticaria and autoimmunity: clinical, laboratory and molecular associations
D1.353 - A Rare Cause of Recurrent Infections: SIFD Syndrome
D1.354 - Possible Association of a MYOF Loss-of-Function Variant With Recurrent Angioedema: Overlap Between Chronic Spontaneous Urticaria and Normal-C1 Hereditary Angioedema? A Case Report
D1.355 - Familial Recurrent Angioedema with Normal C1-Inhibitor: A Clinical Case Series Suggestive of HAE with Normal C1-INH
D1.356 - Atypical association of anti-EJ and anti-RNA polymerase III antibodies in a patient referred for interstitial lung disease
D1.357 - Atypical case of common variable immune deficiency with granulomatous lymphocytic interstitial lung disease
D1.363 - Long-Acting Prophylactic Injection BW-20805: Remarkable and Sustained HAE Attack Reduction — Updated Analysis from an Ongoing Phase 2 Study
D2.449 - Patients with Inadequately Controlled CRSwNP and Blood Eosinophil Count ≥150 cells/µL Experience Benefit with Depemokimab: An Analysis of Data from the Integrated ANCHOR-1/-2 Studies
D2.447 - Phenotyping of Chronic T2 Inflammatory Diseases of the Nose and Paranasal Sinuses and the Algorithm for Biologic Therapy Selection
D2.448 - Recommendations on Patient Education for Biological Therapy in CRSwNP – An EAACI Position Paper
D2.450 - EUFOREA/EPOS Criteria Applied to a Diverse CRSwNP Cohort: Post Hoc Findings from Twice-Yearly depemokimab ANCHOR-1/-2 trials
D2.451 - Real-life upper and lower airway outcomes of long-term dupilumab treatment in patients with severe chronic rhinosinusitis with nasal polyps
D2.452 - Real-World Trends in the Epidemiology and Burden of Chronic Rhinosinusitis with Nasal Polyps Over Time in Germany Reveal Increasing Prevalence and Low Biologic Use
D2.453 - Olfactory outcomes of dupilumab in patients with CRSwNP: A real-world prospective study
D2.455 - Does Biological Therapy Modify NSAID Hypersensitivity? Experience with Omalizumab and Mepolizumab in Patients with Asthma and Nasal Polyps with N-ERD
D2.456 - Chronic sinusitis with nasal polyposis: Add-on aspirin desensitization useful in dupilumab therapy?
D2.457 - Hypersensitivity reactions for Enzyme Replacement Therapy in a Patient with Hunter syndrome
Pagination
Current page
1
Page
2
Next page
Next
Last page
Last
Download the app
The congress at your fingertips
Available on
Download